HealthyPhase 1NCT02173665
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects
A Phase 1 study testing BI 1356 BS - Powder in bottle (PIB) and BI 1356 BS - Tablet in people with Healthy, run by Boehringer Ingelheim.
Trial summary
The objective of the current study was to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 BS. Read more about this study
- Who is it for?
- Ages 21 to 65 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- BI 1356 BS - Powder in bottle (PIB) and BI 1356 BS - Tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- No sites listed yet
- Study dates
- Oct 2004to Dec 2004
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood pressure (BP), Heart Rate (HR), 12-lead Electrocardiogram (ECG)), clinical laboratory tests
- Age ≥21 and Age ≤65 years
- BMI ≥18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Who cannot join
- Any finding of the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
Show all 19Show fewer
- History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients and lactose intolerance)
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of study centre
- Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 110 ms or QTcB > 450 ms or QT >500 ms
About this study
Official title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution
The objective of the current study was to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 BS.
- Conditions
- Healthy
- Being tested
- BI 1356 BS - Powder in bottle (PIB), BI 1356 BS - Tablet, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BI 1356 BS - Powder in bottle (PIB)Drug
BI 1356 BS - TabletDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| BI 1356 BS - Powder in bottle (PIB) | Experimental | Not described Receives: Drug: BI 1356 BS - Powder in bottle (PIB) |
| BI 1356 BS - Tablet | Experimental | Not described Receives: Drug: BI 1356 BS - Tablet |
| Placebo | Active comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with adverse events
Measured: up to 30 days
Number of patients with abnormal findings in physical examination
Measured: Screening, up to 16 days after drug administration
Number of patients with clinically significant changes in vital signs (blood pressure [BP], heart rate [HR])
Measured: Screening, up to 16 days after drug administration
Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)
Measured: Screening, up to 16 days after drug administration
Number of patients with abnormal changes in laboratory parameters
Measured: Screening, up to 16 days after drug administration
Assessment of tolerability by investigator on a 4-point scale
Measured: up to 16 days after drug administration
Secondary outcomes (14)
Cmax (maximum concentration of the analyte in plasma)
Measured: predose, up to 192 h following drug administration
tmax (time from dosing to maximum concentration)
Measured: predose, up to 192 h following drug administration
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Measured: predose, up to 192 h following drug administration
%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)
Measured: predose, up to 192 h following drug administration
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Measured: predose, up to 192 h following drug administration
λz (terminal rate constant in plasma)
Measured: predose, up to 192 h following drug administration
t1/2 (terminal half-life of the analyte in plasma)
Measured: predose, up to 192 h following drug administration
MRTpo (mean residence time of the analyte in the body after po administration)
Measured: predose, up to 192 h following drug administration
CL/F (total clearance of the analyte in the plasma after extravascular administration)
Measured: predose, up to 192 h following drug administration
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Measured: predose, up to 192 h following drug administration
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)
Measured: up to 120 h following drug administration
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Measured: up to 120 h following drug administration
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Measured: up to 120 h following drug administration
Changes of Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma
Measured: predose, up to 96 h following drug administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2014 (estimated)
- Study startOct 2004
- Primary completionDec 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02173665
- Sponsor's protocol ID
- 1218.1
- Status last verified
- Jul 2014
- First submitted
- 24 Jun 2014
- Last updated
- 8 Jul 2014
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution
- ClinicalTrials.gov ID
- NCT02173665
- Acronym / sponsor ID
- 1218.1
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- Oct 2004
- Primary completion
- Dec 2004 (actual)
- First posted
- 25 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the current study was to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 BS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| BI 1356 BS - Powder in bottle (PIB) | Experimental | Drug: BI 1356 BS - Powder in bottle (PIB) |
| BI 1356 BS - Tablet | Experimental | Drug: BI 1356 BS - Tablet |
| Placebo | Active comparator | Drug: Placebo |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood pressure (BP), Heart Rate (HR), 12-lead Electrocardiogram (ECG)), clinical laboratory tests
- Age ≥21 and Age ≤65 years
- BMI ≥18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Key exclusion criteria (19 listed)
- Any finding of the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BI 1356 BS - Powder in bottle (PIB) | Drug | BI 1356 BS - Powder in bottle (PIB) |
| BI 1356 BS - Tablet | Drug | BI 1356 BS - Tablet |
| Placebo | Drug | Placebo |
Primary outcome
Number of patients with adverse events
Time frame: up to 30 days
Number of patients with abnormal findings in physical examination
Time frame: Screening, up to 16 days after drug administration
Number of patients with clinically significant changes in vital signs (blood pressure [BP], heart rate [HR])
Time frame: Screening, up to 16 days after drug administration
Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)
Time frame: Screening, up to 16 days after drug administration
Number of patients with abnormal changes in laboratory parameters
Time frame: Screening, up to 16 days after drug administration
Assessment of tolerability by investigator on a 4-point scale
Time frame: up to 16 days after drug administration
14 secondary outcomes
Cmax (maximum concentration of the analyte in plasma)
Time frame: predose, up to 192 h following drug administration
tmax (time from dosing to maximum concentration)
Time frame: predose, up to 192 h following drug administration
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time frame: predose, up to 192 h following drug administration
%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)
Time frame: predose, up to 192 h following drug administration
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Time frame: predose, up to 192 h following drug administration
λz (terminal rate constant in plasma)
Time frame: predose, up to 192 h following drug administration
t1/2 (terminal half-life of the analyte in plasma)
Time frame: predose, up to 192 h following drug administration
MRTpo (mean residence time of the analyte in the body after po administration)
Time frame: predose, up to 192 h following drug administration
CL/F (total clearance of the analyte in the plasma after extravascular administration)
Time frame: predose, up to 192 h following drug administration
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time frame: predose, up to 192 h following drug administration
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)
Time frame: up to 120 h following drug administration
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Time frame: up to 120 h following drug administration
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time frame: up to 120 h following drug administration
Changes of Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma
Time frame: predose, up to 96 h following drug administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2014.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing BI 1356 BS - Powder in bottle (PIB) and BI 1356 BS - Tablet in people with Healthy, run by Boehringer Ingelheim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with adverse events (time frame: up to 30 days). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2014.